Lantern Pharma Reports Third Quarter 2026 Financial Results and Provides Business Updates
First clinical site engaged for Phase 1b/2 trial in triple negative breast cancer; Taiwan Approvals
First clinical site engaged for Phase 1b/2 trial in triple negative breast cancer; Taiwan Approvals